First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.

doi:10.2147/DDDT.S606617

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.

Drug design, development and therapy - 1 Jan 2026

Zhang Jie, Wang Xiaojia, Xu Huiting, Zang Aimin, Zhao Jun, Chen Jinping, Lei Ruiwen, Zhang Zhen, Hao Chunfang, Liu Yunpeng, Zhou Rongwei, He Lijia, Sun Tao, Ouyang Quchang, Chen Sheng, Xu Jingqiao, Zhou Wei, Shi Yehui, Tong Zhongsheng

Abstract excerpt

Objective: HWH340 is a novel, orally administered poly(ADP-ribose) polymerase inhibitor (PARPi) developed for the treatment of solid tumors with homologous recombination repair (HRR) deficiency. It features a distinct chemical structure that has shown high selectivity and favorable PARP inhibitory and anti-tumor activities in preclinical studies. In this study, we evaluated the safety, tolerability,...

Read the complete abstract on PubMed

Topics

Humans
Poly(ADP-ribose) Polymerase Inhibitors
Female
Middle Aged
Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Adult

Aged

Dose-Response Relationship, Drug

Mutation

Recombinational DNA Repair

Antineoplastic Agents

Maximum Tolerated Dose

Administration, Oral

Piperazines

BRCA1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 42724016
DOI: 10.2147/DDDT.S606617
PMCID: PMC13558385

Genes

BRCA1
BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations.PMID 42724016Read ↗

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsSemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.Semantic proximity Read ↗

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read ↗

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trialsSemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

PARP Inhibition in Cancer: An Update on Clinical DevelopmentSemantic proximity Read ↗

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal CancersSemantic proximity Read ↗

Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degraderSemantic proximity Read ↗

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read ↗

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)Semantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.